- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Video
Future Directions in the Treatment of Atopic Dermatitis
Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, talk about how clinical approaches and understanding of risk/benefit profiles are evolving in light of the emerging long-term data.
Andrew F. Alexis, MD, MPH: Are there any other take-home messages that you have from this paper, Ben?
Benjamin N. Lockshin, MD: That was well said by you. I want to take that as a snippet and leave with that. Regarding this article, I truly believe that when discussing with patients the risks and benefits from alternative agents, we need to go past the primary end points and the early safety data and think about things in the long haul. This addresses that. This is a nice marriage. It’s almost a union between real-world data and clinical trial data.
Andrew F. Alexis, MD, MPH: Thank you. Well, time flies. That was a great discussion, Ben. I want to thank formally thank Dr Lockshin for joining me in this discussion. I truly hope that you, the viewer, enjoyed this episode of [Dermatology Times®] Between the Lines journal club experience. Thank you for tuning in. I hope to see you next time.
Transcript edited for clarity
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
